Scotiabank analyst Paul Cheng upgrades Chevron (NYSE:CVX) from Sector Perform to Sector Outperform.
Goldman Sachs Upgrades Vir Biotechnology to Buy, Raises Price Target to $53
Goldman Sachs analyst Paul Choi upgrades Vir Biotechnology (NASDAQ:VIR) from Neutral to Buy and raises the price target from $41 to $53.